**CLAIMS**:

1. A method of screening a cancer selected from the group consisting of bladder cancer, breast cancer, gastric cancer, esophagus cancer, head and neck cancer and skin cancer wherein LY75 is expressed in said cancer which comprises:-

a) detecting the level of LY75, or one or more fragments thereof in an in vitro biological sample obtained from a subject, wherein the level of LY75, or one or more fragments thereof is detected using an antibody which binds to LY75 using immunohistochemistry and the in vitro biological sample is a bladder, breast, gastric, esophagus, head and neck and skin tissue section; and wherein the presence of LY75 in the biological sample identifies the cancer as likely to respond to treatment with a monoclonal antibody which specifically binds to LY75 and is conjugated to a cytotoxic moiety.

2. The method according to claim 1, wherein the antibody is a monoclonal antibody.

3. The method according to claim 1 or 2, wherein the antibody is a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody.

4. The method according to any one of claims 1 to 3 wherein the antibody contains or is conjugated to a detectable label.

5. The method according to any one of claims 1 to 4 wherein the subject is a human.